Heron Therapeutics, Inc. AXD2.F Stock
Heron Therapeutics, Inc. Price Chart
Heron Therapeutics, Inc. AXD2.F Financial and Trading Overview
Heron Therapeutics, Inc. stock price | 2.93 EUR |
Previous Close | 1.18 EUR |
Open | 1.18 EUR |
Bid | 1.18 EUR x 100000 |
Ask | 1.21 EUR x 100000 |
Day's Range | 1.18 - 1.18 EUR |
52 Week Range | 1.02 - 5.21 EUR |
Volume | 1K EUR |
Avg. Volume | 231 EUR |
Market Cap | 141.26M EUR |
Beta (5Y Monthly) | 0.927464 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.51 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 33.17 EUR |
AXD2.F Valuation Measures
Enterprise Value | 238.17M EUR |
Trailing P/E | N/A |
Forward P/E | -0.71951216 |
PEG Ratio (5 yr expected) | -0.1 |
Price/Sales (ttm) | 1.2410059 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 2.092 |
Enterprise Value/EBITDA | -1.745 |
Trading Information
Heron Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 0.927464 |
52-Week Change | -50.26% |
S&P500 52-Week Change | 20.43% |
52 Week High | 5.21 EUR |
52 Week Low | 1.02 EUR |
50-Day Moving Average | 1.74 EUR |
200-Day Moving Average | 2.74 EUR |
AXD2.F Share Statistics
Avg. Volume (3 month) | 231 EUR |
Avg. Daily Volume (10-Days) | 100 EUR |
Shares Outstanding | 119.72M |
Float | 98.86M |
Short Ratio | N/A |
% Held by Insiders | 0.31% |
% Held by Institutions | 102.54% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -132.57% |
Operating Margin (ttm) | -122.46% |
Gross Margin | -42.36% |
EBITDA Margin | -119.92% |
Management Effectiveness
Return on Assets (ttm) | -35.22% |
Return on Equity (ttm) | -2408.87% |
Income Statement
Revenue (ttm) | 113.83M EUR |
Revenue Per Share (ttm) | 1.01 EUR |
Quarterly Revenue Growth (yoy) | 26.30% |
Gross Profit (ttm) | -50508000 EUR |
EBITDA | -136512000 EUR |
Net Income Avi to Common (ttm) | -150904000 EUR |
Diluted EPS (ttm) | -1.29 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 60.02M EUR |
Total Cash Per Share (mrq) | 0.5 EUR |
Total Debt (mrq) | 156.93M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 2.287 |
Book Value Per Share (mrq) | -0.096 |
Cash Flow Statement
Operating Cash Flow (ttm) | -127873000 EUR |
Levered Free Cash Flow (ttm) | -69407624 EUR |
Profile of Heron Therapeutics, Inc.
Country | Germany |
State | CA |
City | San Diego |
Address | 4242 Campus Point Court |
ZIP | 92121 |
Phone | 858 251 4400 |
Website | https://www.herontx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 203 |
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Q&A For Heron Therapeutics, Inc. Stock
What is a current AXD2.F stock price?
Heron Therapeutics, Inc. AXD2.F stock price today per share is 2.93 EUR.
How to purchase Heron Therapeutics, Inc. stock?
You can buy AXD2.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Heron Therapeutics, Inc.?
The stock symbol or ticker of Heron Therapeutics, Inc. is AXD2.F.
Which industry does the Heron Therapeutics, Inc. company belong to?
The Heron Therapeutics, Inc. industry is Biotechnology.
How many shares does Heron Therapeutics, Inc. have in circulation?
The max supply of Heron Therapeutics, Inc. shares is 151.2M.
What is Heron Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Heron Therapeutics, Inc. PE Ratio is now.
What was Heron Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Heron Therapeutics, Inc. EPS is -0.51 EUR over the trailing 12 months.
Which sector does the Heron Therapeutics, Inc. company belong to?
The Heron Therapeutics, Inc. sector is Healthcare.